Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).

Biliary tract cancer (BTC) patients who have undergone surgical resection with major hepatectomy cannot tolerate the standard gemcitabine regimen (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks) due to severe toxicities such as myelosuppression. Our dose-finding study of adjuvant gemcitabine therapy...

詳細記述

書誌詳細

出版年:	PLoS ONE
主要な著者:	Yutaka Fujiwara, Shogo Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori Toyoda, Tetsuo Ajiki, Yuki Takashima, Kenichi Yoshimura, Akinobu Hamada, Hironobu Minami, Tatsuya Ioka
フォーマット:	論文
言語:	英語
出版事項:	Public Library of Science (PLoS) 2015-01-01
オンライン･アクセス:	http://europepmc.org/articles/PMC4669083?pdf=render